By Shoshanna Solomon

Currency’s strength against dollar reaches level not seen in over 2 decades, and experts predict it is not going to stop there

A critical mass of mega-valued global tech companies based in Israel may create a whole new local ecosystem in the coming years.

Google, Microsoft, Facebook, Intel and Nvidia are setting up or expanding their Israeli chip design operations, and local firms are seeing a renaissance as VC money rolls in.

The half-year figure exceeds the record-breaking $2.9B in investments for all of 2020; 7 of Israel’s 13 cybersecurity unicorns were created in first half of 2021.

Once shunned by local firms, the TASE is now seeing massive growth and hoping to use dual-listings to lure the biggest prizes yet: unicorns.

Bank of Israel report says Israel must invest more in its people, develop its infrastructure and upgrade its financial system in order to eventually reduce income inequality.

IAI’s subsidiary Elta and Soroka will set up a joint innovation center where doctors and defense engineers will seek out solutions.

Contracts ensure continuity of service even if tech giants may come under pressure to boycott Israel, Finance Ministry officials say.

The Tel Aviv company, with HQ in London, will test out its technology with pro soccer teams; it aims to become a standard device for games.

Steering committee creates draft model of possible future central bank-backed digital currency as chatter on virtual payments grows globally.

Tech developed by Helios melts lunar soil to extract oxygen for fuel, enabling lower payloads and lower costs for space missions.

Even amid pandemic challenges, VC funds added a total of 620 new firms to their portfolios, up from 470 in 2019 and 439 in 2014, report shows.

Reopening the economy requires balancing individual rights, including of inoculation-refusers, with public welfare, but the government hasn’t weighed in definitively

Tel Aviv-based company posts 2020 revenue of $989 million in ‘phenomenal year’; net loss for year widens to $216 million vs net loss of $86 million in 2019 as costs jump.

Biond Biologics hopes its therapy, which activates three separate immune pathways, will prove to be ‘strong and sustained anti-tumor response,’ says CEO; human trials to start mid-2021